Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) versus Tenon Medical (NASDAQ:TNON)

Tenon Medical (NASDAQ:TNONGet Free Report) and TriSalus Life Sciences (NASDAQ:TLSIGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Volatility & Risk

Tenon Medical has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tenon Medical and TriSalus Life Sciences”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tenon Medical $3.32 million 1.41 -$15.58 million ($27.23) -0.05
TriSalus Life Sciences $26.89 million 6.32 -$59.04 million ($2.49) -2.24

Tenon Medical has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Tenon Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.7% of Tenon Medical shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 4.7% of Tenon Medical shares are held by insiders. Comparatively, 32.8% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tenon Medical and TriSalus Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tenon Medical -413.88% -1,785.88% -164.26%
TriSalus Life Sciences -206.24% N/A -236.83%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Tenon Medical and TriSalus Life Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenon Medical 0 0 2 0 3.00
TriSalus Life Sciences 0 0 7 2 3.22

Tenon Medical currently has a consensus price target of $5.50, suggesting a potential upside of 269.13%. TriSalus Life Sciences has a consensus price target of $11.79, suggesting a potential upside of 111.59%. Given Tenon Medical’s higher possible upside, analysts plainly believe Tenon Medical is more favorable than TriSalus Life Sciences.

Summary

TriSalus Life Sciences beats Tenon Medical on 9 of the 15 factors compared between the two stocks.

About Tenon Medical

(Get Free Report)

Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Receive News & Ratings for Tenon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenon Medical and related companies with MarketBeat.com's FREE daily email newsletter.